The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
By L. Caly, J. Druce, M. Catton, D. Jans, K. Wagstaff. Antiviral Research, 2020
1,960 citations recorded by the source corpus.
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
Subfields: Infectious Diseases, Parasitology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/ed7608398de967b45d570029be88e3a60cd734d9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment (2020, methodology): “Caly et al. (2020) have demonstrated Ivermectin-treatment can reduce 5000- fold viral RNA load compared to the control sample in cell cultural at 48 h, but no further reduction observed at 72 h. Mulangu et al. (2019) have conducted a trial of four investigational therapies for Ebola virus diseased…”
- Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor (2021, positive): “We also tested Ivermectin, another FDA-approved nuclear transport inhibitor, that had been suggested as a putative inhibitor for SARS-CoV-2 Orf6 [3].”
- COVID-19: Transmission, prevention, and potential therapeutic opportunities (2020, positive): “adding five μM of Ivermectin to virus-infected Vero/hSLAM cells reduced the levels of viral RNA by 5,000 times after 48-hour culture [178].”
- Sarbecovirus ORF6 proteins hamper induction of interferon signaling (2021, background): “Two recent reports suggested that the compounds ivermectin (Caly et al., 2020) and selinexor (Gordon et al.”
- A Review of SARS-CoV-2 and the Ongoing Clinical Trials (2020, background): “Recently, an in vivo study has proven Ivermectin's capability to reduce viral RNA up to 5,000-fold after 48 h of infection with SARS-CoV-2 [52] .”